James Hurn-Joung Lee is a notable inventor based in Saint Paul, MN (US). He has made significant contributions to the field of dermatology, particularly in the treatment of actinic keratosis. With a total of 2 patents, his work focuses on improving patient outcomes through innovative pharmaceutical formulations.

Latest Patents

Lee's latest patents include a groundbreaking 2x2x2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimod. This patent outlines methods for the topical or transdermal delivery of imiquimod, aimed at providing effective treatment with shorter therapy durations compared to the currently available Aldara® 5% imiquimod cream. His formulations are designed to deliver an efficacious dose of imiquimod while maintaining an acceptable safety profile, making treatment more convenient for patients.

Career Highlights

James Hurn-Joung Lee is associated with Medicis Pharmaceutical Corporation, where he has been instrumental in developing innovative treatments for skin conditions. His work has been recognized for its potential to enhance the quality of life for patients suffering from actinic keratosis.

Collaborations

Lee has collaborated with esteemed colleagues, including Michael T Nordsiek and Sharon F Levy, to advance research and development in dermatological therapies. Their combined expertise has contributed to the successful formulation of new treatment options.

Conclusion

James Hurn-Joung Lee's contributions to dermatology through his innovative patents and collaborations highlight the importance of research in developing effective treatments for skin conditions. His work continues to pave the way for advancements in patient care and treatment methodologies.

This text is generated by artificial intelligence and may not be accurate.